

Attorney Docket No.: 10127.200-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: P. Mortensen

Confirmation No: 9691

Serial No.: 10/057,431

Group Art Unit: 1645

Filed: January 25, 2002

Examiner: E. Dejong

For: Method of Analyzing Granular Composition by Fluorescence Analysis

**INFORMATION DISCLOSURE STATEMENT (IDS) UNDER 37 CFR 1.97(d)**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which may be material to the patentability of this application and with respect to which there may be a duty to disclose. While the references may be material under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are prior art. The filing of this IDS shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO/SB/08A, which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is enclosed.

It is respectfully requested that these references be considered by the USPTO in its examination of the above-identified application and be made of record therein.

This IDS is being filed after the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution, but before, or simultaneously with, the payment of the issue fee. In accordance with 37 C.F.R. § 1.97(d), Applicants enclose the statement specified in 37 C.F.R. § 1.97(e) and the fee set forth in 37 C.F.R. § 1.17(p).

The required fee, estimated to be \$180, was charged to Novozymes North America, Inc.'s Deposit Account No. 50-1701 at the time of electronic filing. The USPTO is authorized to charge this Deposit Account should any additional fees be due.

Respectfully submitted,

Date: January 23, 2009

/Michael W. Krenicky, Reg. # 45411/  
Michael W. Krenicky, Reg. No. 45,411  
Novozymes North America, Inc.  
500 Fifth Avenue, Suite 1600  
New York, NY 10110  
(212) 840-0097